Yujie DAI, Lingyao LIAO, Yibo QIU, et al. Molecular mechanism of estrogen receptor alpha-36 in 17β-estradiol-promoted proliferation in human papillary thyroid carcinoma cells[J]. Journal of Third Military Medical University, 2017, 39(24): 2380-2384.
DOI:
Yujie DAI, Lingyao LIAO, Yibo QIU, et al. Molecular mechanism of estrogen receptor alpha-36 in 17β-estradiol-promoted proliferation in human papillary thyroid carcinoma cells[J]. Journal of Third Military Medical University, 2017, 39(24): 2380-2384. DOI: 10.16016/j.1000-5404.201706001.
Molecular mechanism of estrogen receptor alpha-36 in 17β-estradiol-promoted proliferation in human papillary thyroid carcinoma cells
To determine the effect of estrogen receptor-α36 (ERα36) on 17β-estradiol (E2)-promoted proliferation in papillary thyroid carcinoma (PTC) cells
and investigate the underlying mechanisms possibly involved.
Methods
2
ERα36 protein expression was analyzed in 34 PTC tissue samples and 21 matched paracancerous tissues by immunohistochemical assay (S-P). Protein level of ERα36 in PTC cell lines BCPAP and K-1 in presence and absence of E2 (10
-7
10
-8
and 10
-9
mol/L) was detected by Western blotti
ng. The levels of phosphorylated ERK1/2 and AKT were analyzed in the BCPAP and K-1 cells with 10
-8
mol/L E2 treatment by Western blotting. The BCPAP and K-1 cells were assigned into control
E2
E2+scrambled siRNA
and E2+ERα36-siRNA groups. The effect of ERα36-siRNA on the expression of above proteins was tested by Western blotting. Proliferation of BCPAP cells after the treatment of gradient doses of E2 was measured by MTT assay
and the effect of ERα36-siRNA on the proliferation was also studied.
Results
2
The positive rates of ERα36 were 82.4% in PTC tissues
which were significantly higher than those in adjacent normal tissues (
P
<
0.05). Both BCPAP and K-1 cells expressed ERα36
and 10
-8
mol/L E2 treatment enhanced the expression level in a time-dependent manner. E2 treatment also resulted in increases in the phosphorylation of ERK1/2 and AKT
and most significant increases were observed in 15 min after the treatment in the BCPAP cells and 10 min in the K-1 cells. However
ERα36-siRNA inhibited these above promotions. What's more
E2 induced cell proliferation in the BCPAP cells
which was suppressed by ERα36-siRNA.
Conclusion
2
ERα36 may medicate E2-promoting proliferation of PTC cells through ERK/AKT pathway.
关键词
Keywords
references
DALAL V, KAUR M, BANSAL A. Papillary carcinoma thyroid with anastomosing channels: An unusual morphology[J]. J Lab Physicians, 2017, 9 (2): 140-142. DOI: 10.4103/0974-2727.199631.
RAHBARI R, ZHANG L, KEBEBEW E. Thyroid cancer gender disparity[J]. Future Oncol, 2010, 6(11):1771-1779. DOI: 10.2217/fon.10.127.
DERWAHL M, NICULA D. Estrogen and its role in thyroid cancer[J]. Endocr Relat Cancer, 2014, 21(5):T273-283. DOI: 10.1530/ERC-14-0053.
PRZYBYLIK-MAZUREK E, HUBALEWSKA-DYDEJCZYK A, FEDOROWICZ A, et al. Factors connected with the female sex seem to play an important role in differentiated thyroid cancer[J]. Gynecol Endocrinol, 2012, 28(2):150-155. DOI: 10.3109/09513590.2011.563909.
WANG Z, ZHANG X, SHEN P, et al. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66[J]. Biochem Biophys Res Commun, 2005, 336(4):1023-1027. DOI: 10.1016/j.bbrc.2005.08.226.
CHAUDHRI R A, SCHWARTZ N, ELBARADIE K, et al. Role of ERα36 in membrane-associated signaling by estrogen[J]. Steroids, 2014, 81: 74-80. DOI: 10.1016/j.steroids.2013.10.020.
TANG C, YANG L, WANG N, et al. Expression and significance of GPER1, EGFR and CXCR1 in papillary thyroid carcinoma [J]. J Third Mil Med Univ, 2014, 36(12):1317-1321.
ZHAO L, TANG C, YANG L, et al. Expression and significance of Caveolin-1, GPR30 and Vimentin in papillary thyroid carcinoma [J]. Chin J Immunol, 2015, 31(11):1510-1514. DOI: 10.3969/j.issn.1000-484X.2015.11.015.
LIN S L, YAN L Y, ZHANG X T, et al. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways[J ] . PLoS ONE, 2010, 5(2):e9013. DOI: 10.1371/journal.pone.0009013.
YIN L, ZHANG X T, BIAN X W, et al. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells[J]. PLoS ONE, 2014, 9(9):e107369. DOI: 10.1371/journal.pone.0107369.
CHAUDHRI R A, OLIVARES-NAVARRETE R, CUENCA N, et al. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36)[J ] . J Biol Chem, 2012, 287(10):7169-7181. DOI: 10.1074/jbc.M111.292946.